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Introduction
Carbon monoxide (CO) is a colorless, odorless
yet highly toxic gas. It is a by-product of the incom-
plete combustion of hydrocarbons commonly found
in engine exhaust and heating units that burn oils,
coal, and kerosene(1). CO intoxication is one of the
leading causes of poison related injury in the mod-
ern world(2). Although small amounts of CO are
needed for normal physiological functioning,
exogenous exposure is toxic(3). CO induces toxicity
through hypoxic and inflammatory pathways(4). CO
quickly binds hemoglobin to create carboxyhemo-
globin and deprive tissues of oxygen(3). With high
demands for oxygen, the brain and heart are most
susceptible to injury(4). Inflammation occurs with a
more gradual progression due to the oxidative stress
brought on by increased levels of cytosolic heme
and heme oxygenase-1. Although inflammation
occurs independent of hypoxia, it has also been
invoked as a cause for cardiac and neurological
injury. Yet, the level of carbon monoxide needed to
cause inflammation is uncertain(3). Hyperbaric oxy-
gen therapy (HBO2) is the primary method of treat-
ment for CO poisoning and for local tissue anoxia,
and its urgent application is universally accepted(3, 5-
7). Although elevated carboxyhemoglobin levels
indicate previous exposure to CO, the level does
not correlate with clinical symptoms or long-term
prognosis(4). CO poisoning involves a wide array of
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ABSTRACT
Objective: The present study was conducted in attempt to identify reliable biomarkers in predicting the severity of neurological
injury. 
Materials and methods: A number of 30 patients with confirmed CO poisoning and a number of 7 healthy control volunteers
were involved into the study. All participants received at least 60 minutes of hyperbaric oxygen therapy (HBO2) at 2.5 atmospheres
absolute (ATA). Standard blood gas analysis was performed on 10 mL venous blood samples obtained immediately before and after
HBO2. Seven biomarkers and carboxyhemoglobin (COHb) levels were measured. 
Results: Following HBO2, all patients recovered fully and were discharged in stable condition. Significant differences between
pre and post HBO2 values were found in three of the seven biomarkers analyzed: TNF-alpha, IL-10, and S100B. Additionally, S100B
and NSE levels were significantly different from controls for the 10 patients who experienced temporary loss of consciousness (LOC),
and IL-6 levels were significantly different from controls for all CO-intoxicated patients. 
Conclusion: Conclusive evidence of a correlation between a single biomarker and LOC patients was not found. However, the
data suggests that the significance of the fall between pre and post HBO2 values for TNF-alpha and IL-10, along with the resolution of
IL-6 levels, may herald the severity of the patient's neurological condition. 
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symptoms that may be attributed to various other
conditions. This high variability in signs and clini-
cal symptoms of CO poisoning, combined with a
lack of specific diagnostic tools, makes it very diffi-
cult to identify the severity and further progression
of both cardiac and neurological injury. While pre-
vious studies have identified reliable biomarkers for
predicting cardiac injury, namely troponin-T and N-
terminal pro-brain natriuretic peptide (NT-pro
BNP), analogous biomarkers for brain injury have
not been found(8).  A number of reports have
described increases in neuron specific enolase
(NSE) and S100B proteins as possible indicators of
neurological damage, but the results have been
inconclusive(1,9-11). The absence of a correlation
between carboxyhemoglobin levels and severity of
the clinical outcome suggests that other processes
such as inflammation, rather than hypoxia, may be
indicative of final evolution and later outcomes(3).
We therefore analyzed the levels of inflammatory
and brain specific markers in a recent series of CO-
intoxicated patients and healthy volunteers, to iden-
tify a possible correlation between biomarkers and
adverse neurological sequelae. We hypothesized
that elevations in specific biomarkers and signifi-
cant reductions after hyperbaric treatment may cor-
relate with neurological injury severity. 
Materials and methods
The public hyperbaric facility at the Vaio
Hospital, near Parma, Italy, received and treated all
participants (CO-intoxicated patients transferred in
from up to 200 miles away). The standard protocol
approved by the Ethics Committee at Vaio Hospital
mandates the collection of 10 mL venous blood
samples immediately before and after HBO2 treat-
ment for adult patients of suspected CO poisoning
to evaluate the severity of intoxication and to guide
clinical treatment. This standard protocol was pre-
sented to the Vaio Hospital Ethics Committee and
deemed exempt from acquiring individual patient
consent due to the urgency of treatment, possible
unconsciousness of subjects, and the small quantity
of blood collected. Abnormal results have been dis-
closed to all patients. The study protocol also
addressed the potential utility of obtaining HBO2
blood samples from healthy volunteers, namely the
physicians and nurses accompanying the patient
inside the multiplace hyperbaric chamber for assis-
tance. These clinicians all gave written, informed
consent to the study.
In this study, 30 patients admitted from
10/2013 to 12/2013 were evaluated. Following pro-
tocol, blood samples were taken immediately
before and after HBO2. As some patients were
transferred to the Hospital from outside Emergency
Room facilities, the COHb levels obtained at those
initial facilities of presentation were also used in
our final calculations. 
HBO2 was initiated urgently, within a few
hours of the CO exposure, and consisted of 2.5 ATA
O2 for 60 minutes, including compression and
decompression times. The 10 patients who had been
rescued with loss of consciousness (LOC) received
an additional 30 minutes of HBO2 at 2.8 ATA
before the 2.5 ATA treatments.  
Study population 
Our analysis excluded patients who were
admitted comatose and/or intubated, as these
patients often present with longer delays and require
more complex management. Identical measures
were obtained from all 30 patients with confirmed
CO poisoning and from the 7 healthy, asymptomatic
control volunteers. All patients and volunteers
received 60min of HBO2 at 2.5 ATA. The 30
patients were divided into two groups: loss of con-
sciousness (LOC) and no loss of consciousness (No
LOC). Patients in the LOC group experienced tran-
sient loss of consciousness immediately after CO
exposure, but all regained consciousness by the time
HBO2 was initiated; whereas the patients in the No
LOC group remained conscious from the time of
exposure to treatment. All patients, therefore, were
conscious at the time of initiating HBO2. Beyond
the standard 60 minutes of HBO2 at 2.5 ATA given
to all patients, LOC patients received an initial addi-
tional 30 minutes of HBO2 at 2.8 ATA. Patients
were evenly split male-female, and there were no
differences in mean age between LOC and No LOC
patients nor in starting COHb values, which are
reported here from the initial admission data from
peripheral hospitals (Table 1). The seven healthy
volunteers were all adult operational support person-
nel, either physicians or nurses, familiar with HBO2
exposure. Venous blood samples were obtained
immediately before and after HBO2 and analyzed
via ELISA Kit. Additional measured data included:
interleukin (IL)-6, IL-8, IL-10, C-reactive protein
(CRP), tumor necrosis factor-alpha (TNF-α), neu-
ron-specific enolase (NSE), and S100B protein.
COHb levels upon first presentation were also
reported from blood samples taken at the
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Emergency Rooms of original. Data Collection and
Measurements presentation and, when available, are
shown in Table 1.
Patient outcome and follow-up 
All patients improved and were asymptomatic
after receiving a single round of hyperbaric treat-
ment. Neurologic evaluations were performed at
arrival and daily until discharge, if admitted to the
Hospital. Follow-up telephone interviews were
completed for all patients at 10, 20, and 30 days
post HBO2. 
Data analysis 
We hypothesized that elevations in specific
biomarkers may correlate with adverse neurological
sequelae. Maximum differences in pre and post
HBO2 biomarker values were expected in the most
severely poisoned patients, the LOC group. We test-
ed if the levels of certain biomarkers could be used
to identify the patients most at-risk to develop late
sequelae. Statistical analysis was performed using
SPSS statistical software vers. 18 (SPSS, Inc.,
Chicago). Pre and post HBO2 biomarker values
from all patient groups were compared against con-
trols using unpaired t-tests with significance set at
0.05. Pre vs post HBO2 biomarker values were
compared within patient groups using Wilcoxon
two-tailed signed-ranks tests with significance set
at 0.05. 
Results
Following HBO2, all patients recovered fully
and were discharged from the hospital in stable
condition. Neurologic symptoms were observed at
the beginning of HBO2 treatment in 5 patients: 4
reported confusion and malaise and 1 complained
of a headache. 
All neurologic symptoms resolved after 1
HBO2 without long-term sequelae on follow-up by
telephone interviews 10, 20, and 30 days after
HBO2. Significant differences between pre and
post HBO2 values were found in three of the seven
biomarkers analyzed: TNF-alpha values (Fig. 1)
were significantly different for the All combined
patient group and for the No LOC patient group;
IL-10 values (Fig. 2) were significantly different for
the All patient group only; and S100B values were
significantly different for all three groups (Fig. 3).
These significant pre and post HBO2 differences
found in TNF-alpha, IL-10, and S100B were not
observed in the controls.
Tables 2 and 3 display mean values and signif-
icance for all biomarkers. All three patient groups
exhibited a significant decrease in COHb levels
after HBO2 (Table 1). LOC patients had slightly
higher COHb presenting values, but not significant-
ly different from patients without LOC.
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Fig. 1: TNF-α pre and post-HBO2 values for controls
and patient groups. *Values are significant.  
Fig. 2: IL-10 pre and post-HBO2 values for controls and
patient groups. *Values are significant.  
Fig. 3: IS100B pre and post-HBO2 values for controls
and patient groups. *Values are significant.  
Mean COHb levels for LOC and No LOC
patient groups were 26.8% and 23.1%, respectively.
In controls, low COHb levels without significant
changes were found. Aside from pre and post
HBO2 value differences, concentrations of three
biomarkers were significantly different from con-
trols for at least one patient group: S100B and NSE
were significantly different from controls for the
LOC patient group and IL-6 was significantly dif-
ferent from controls for all three patient groups
(All, LOC, and No-LOC).  
Discussion 
CO exposure causes a release of various pro-
teins into the bloodstream via hypoxic and inflam-
matory pathways, either of which may herald neu-
rological damage. Previous toxicology data from
CO poisoning patients has shown that acute inflam-
matory modulation may mediate such neurological
toxicity(8, 12). Our study thus analyzed proteins with
suspected involvement in both pathways. TNF-
alpha, IL-6, IL-8, and IL-10 are inflammatory
mediators, while S100B and NSE are neural tissue
proteins characteristic of hypoxic injury(12).
Previous studies have suggested that S100B
and NSE, proteins released from neuronal and
astroglial cells following hypoxic brain injury, may
be indicative of neurological deficit. However, the
evidence is inconclusive. Brvar et al. found elevat-
ed S100B levels in unconscious patients exposed to
CO for a long period of time, but only one of those
patients had any neurological sequelae at discharge.
No S100B elevation was found in patients who
experienced only transitory unconsciousness(9).
Rasmussen et al. found no changes in either
S100B or NSE levels after CO poisoning(11). Both
Cakir et al. and Yardan et al. noted increased S100B
levels but not NSE levels. However, only Cakir
reported considerable decreases in NSE and S100B
after HBO2. Yardan found no difference in either
S100B or NSE levels after HBO2(1, 12, 13). Our results
add further ambiguity to the role of S100B and
NSE in predicting neurological injury. In regards to
S100B, we found no difference when compared to
controls. NSE levels were significantly different
from controls in the LOC patient group only. In
comparing pre and post HBO2 values, however, all
patient groups experienced a significant change in
S100B while no patient groups experienced a sig-
nificant change in NSE. Furthermore, our S100B
data differs from all other reports in that our
patients presented with initially low S100B levels
that subsequently rose following HBO2, rather than
initially high levels that later fell. In addition to our
analysis of S100B and NSE as suspected products
of hypoxic injury, we also evaluated the levels of
various inflammatory mediators, particularly TNF-
alpha, IL-6, IL-8, and IL-10. We hypothesized that
these proteins, which are involved in the inflamma-
tory rather than hypoxic path of CO intoxication,
might be more telling of neurological injury.
Our results indicate that a rapid decrease in the
inflammatory proteins TNF-alpha and IL-10 after
HBO2 may predict the resolution of neurologic
symptoms; while protein levels that remain elevat-
ed after HBO2 may be indicative of neurological
complications. We propose further study of TNF-
alpha and IL-10 monitoring in CO poisoning
patients as a marker of neurological complications,
especially if residual symptoms persist after HBO2.
Limitations
There are several limitations to our study. We
only analyzed 30 patients (10 LOC patients and 20
No-LOC patients). While this small sample size
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provides a basis for identifying significant differ-
ences in biomarkers, it is not a fully exhaustive
approach. To fully identify all biomarker levels
with significant differences between pre and post-
HBO2 values, future studies are needed. For exam-
ple, in our LOC patient group, pre and post-HBO2
TNF-α value differences approached significance,
but, with a p-value of 0.06, did not meet the 0.05
significance level. Additionally, as all patients expe-
rienced only mild CO intoxication and none experi-
enced major neurological symptoms, the homo-
geneity of the study population suggests that our
results do not constitute a proof but rather provide a
strong suspicion of which biomarkers might herald
neurological sequelae. Finally, the delay in taking
blood samples might also influence results.
Although COHb levels were taken at the ER of
original presentation, blood samples for biomarker
analysis were not taken until right before HBO2
treatment. As plasma biomarker levels vary greatly
over time, temporal adjustments to blood collection
could offer better discrimination of patient groups.
A prospective study involving the use of objective
neuropsychological testing is planned to more accu-
rately assess whether our evidenced variations in
plasma proteins provide the objective method for
stratifying CO poisoning we suspect. 
Conclusion
Overall, we did not produce conclusive evi-
dence of a correlation between a single biomarker
and neurological complications. However, we
found that two inflammatory mediators, IL-10 and
TNF-alpha, decreased significantly for the All
patient group following HBO2. Although statisti-
cally unclear due to our small sample size, this dif-
ference is likely greater for LOC patients.
Additionally, we found that IL-6 was significantly
elevated in all three patient groups when compared
to controls and that after HBO2, these IL-6 levels
dropped to levels very similar to that of controls.
Our data suggests that the significance of the fall
between pre and post HBO2 values for TNF-alpha
and IL-10, along with the resolution of IL-6 levels,
may herald the gravity of the patient’s neurological
condition. We propose further investigation into
TNF-alpha, IL-10, and IL-6 concentrations in CO-
intoxicated patients to better evaluate the efficacy
of these biomarkers as indicators of neurological
complications. 
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